Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.

MLA

Berchuck, Jacob E., et al. “Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.” JCO Precision Oncology, Sept. 2022, pp. 1–12. EBSCOhost, https://doi.org/10.1200/PO.22.00329.

APA

Berchuck, J. E., Boiarsky, D., Silver, R., Sunkara, R., McClure, H. M., Tsai, H. K., Siegmund, S., Tewari, A. K., Nowak, J. A., Lindeman, N. I., Rana, H. Q., Choudhury, A. D., Pomerantz, M. M., Freedman, M. L., Van Allen, E. M., & Taplin, M.-E. (2022). Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precision Oncology, 1–12. https://doi.org/10.1200/PO.22.00329

Chicago

Berchuck, Jacob E., Daniel Boiarsky, Rebecca Silver, Rajitha Sunkara, Heather M. McClure, Harrison K. Tsai, Stephanie Siegmund, et al. 2022. “Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.” JCO Precision Oncology, September, 1–12. doi:10.1200/PO.22.00329.